-3 RECOMBINANT ADENOVIRAL VECTOR EXPRESSING CANINE INTERFERON LAMBDA-3

The present invention provides a recombinant adenoviral vector expressing canine interferon lambda-3. A recombinant target protein obtained by cells transformed with the vector has an excellent inhibitory effect against canine influenza virus, and thus can be used as a pharmaceutical composition for the treatment of diseases caused by viruses including canine influenza virus..

Medienart:

Patent

Erscheinungsjahr:

2022

Erschienen:

2022

Enthalten in:

Europäisches Patentamt - (2022) vom: 27. Dez. Zur Gesamtaufnahme - year:2022

Sprache:

Englisch

Beteiligte Personen:

CHOI IN SOO [VerfasserIn]
KIM DONG HWI [VerfasserIn]
GO HYEON JEONG [VerfasserIn]
AHN HEE SEOP [VerfasserIn]
KIM DAYOON [VerfasserIn]
KIM JAEHYEONG [VerfasserIn]
PARK BYUNGJOO [VerfasserIn]
PARK SEUNG YONG [VerfasserIn]
SONG CHANG SEON [VerfasserIn]
SANG WON LEE [VerfasserIn]
JOONG BOK LEE [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A61K: Preparations for medical, dental, or toilet purpose (...)
A61P: Specific therapeutic activity of chemical compounds (...)
bio
C07K: Peptides (peptides containing β-lactam rings c07d; (...)
C12N: Microorganisms or enzymes; compositions thereof; pr (...)
che

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2022-12-27, Last update posted on www.tib.eu: 2023-12-20, Last updated: 2023-12-29

Patentnummer:

KR20220169275

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA016436695